Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

NEW ISSUE: Fresenius Medical Care € bmk Long 5yr Sr Unsec; MS+130a

IGC European Market: Deal Flow - General

Issuer

Term

Maturity

Size

Ranking

Type

ISIN

IPT

Fresenius Medical Care

Long 5yr

16-Feb-32

bmk

Sr Unsec

Fixed

XS3523247875

MS+130a


IPTs: 5yr: MS+130a


  • Issuer: Fresenius Medical Care AG (Ticker: FMEGR, Country: DE)
  • Issuer LEI: 549300CP8NY40UP89Q40
  • Issuer Ratings: Baa3 (stable) by Moody's / BBB- (stable) by S&P / BBB- (stable) by Fitch
  • Exp. Issue Ratings: Baa3 by Moody's / BBB- by S&P / BBB- by Fitch
  • Format: Senior Unsecured, Reg S Bearer
  • Settlement: 16-Nov-26 (T+5)
  • Size: € Benchmark
  • Tenor: Long 5 Year
  • Maturity Date: 16-Feb-32
  • Coupon Type: Fixed, Annual, Act/Act (ICMA), short first
  • Par Call: 3-month
  • ISIN: XS3523247875
  • Documentation: DIP / Lux. Stock Exchange (regulated market) / German Law / €1k + €1k
  • Optional Redemption: Change of Control / Clean-up Call (80%) / Tax Call
  • Selling Restrictions: Regulation S and as per the base prospectus of Fresenius Medical Care AGs Debt Issuance Programme dated 14-Aug-26 and supplemented on 09-Oct-26 and 06-Nov-26 (the Base Prospectus)
  • Use of Proceeds: General corporate purposes, including refinancing of outstanding indebtedness
  • MiFID II Target Market: Eligible counterparties and professional clients (all distribution channels), and retail clients (appropriate distribution channels). No PRIIPS KID necessary
  • Active Bookrunners: BNP Paribas, Goldman Sachs Bank Europe SE, ING (B&D) and UniCredit
  • Advertisement: The Base Prospectus and the final terms, when published, will be available at https://www.luxse.com/issuer/FreseniusMedCar/61721
  • Stabilisation: FCA/ICMA stabilisation applies
  • Timing: Today's business
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.